TY  - CONF

T1  - Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial

JO  - JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

PY  - 2021/01/01

AU  - Paller AS

AU  - Weidinger S

AU  - Cork MJ

AU  - Marcoux D

AU  - Katoh N

AU  - Zhang H

AU  - Rossi AB

AU  - Shumel B

AU  - Zhang A

AU  - Prescilla R

AU  - Chao J

ED  - 

VL  - 85

IS  - 3

SP  - AB141

EP  - AB141

Y2  - 2024/12/22

ER  -